CN220554555U - Non-bracket fixed levonorethindrone intrauterine drug delivery device - Google Patents
Non-bracket fixed levonorethindrone intrauterine drug delivery device Download PDFInfo
- Publication number
- CN220554555U CN220554555U CN202321660905.2U CN202321660905U CN220554555U CN 220554555 U CN220554555 U CN 220554555U CN 202321660905 U CN202321660905 U CN 202321660905U CN 220554555 U CN220554555 U CN 220554555U
- Authority
- CN
- China
- Prior art keywords
- intrauterine
- storage tank
- wire
- fixed
- levonorgestrel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 43
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 25
- 229960004400 levonorgestrel Drugs 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims description 16
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 7
- -1 polyethylene Polymers 0.000 claims description 7
- 210000004291 uterus Anatomy 0.000 claims description 6
- 230000003387 muscular Effects 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229940053934 norethindrone Drugs 0.000 claims 5
- 201000009273 Endometriosis Diseases 0.000 abstract description 4
- 210000000754 myometrium Anatomy 0.000 abstract description 3
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 2
- 208000005641 Adenomyosis Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 208000016018 endometrial polyp Diseases 0.000 description 2
- 201000009274 endometriosis of uterus Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 206010046811 uterine polyp Diseases 0.000 description 2
- 206010017472 Fumbling Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
The utility model relates to a bracket-free fixed levonorgestrel intrauterine drug delivery device. The device comprises a medicine storage tank, a head wire and a tail wire, wherein the rear end of the head wire is fixedly connected with the medicine storage tank through a connecting ring, and an intrauterine fixing knot is arranged at the front end of the head wire. The utility model provides a design idea that a linear structure is used for replacing a support structure to fix a medicine container in a uterine cavity for the first time, and an intrauterine fixing knot is buried and fixed in the middle position of the intrauterine layer by using the physiological thickness of the myometrium through a Gong Nahuan placer, so that good fixation is realized. By using the device, the medicine storage tank can be firmly fixed in the uterine cavity without fixing a bracket, no matter whether the size of the uterine cavity and the cervical canal of a patient are loose or not, the medicine storage tank can be ensured not to shift or fall off, and the tolerance of the patient is better. The device is used for treating endometriosis, dysmenorrhea and menorrhagia, and can be used for contraception, ensuring the continuity and effectiveness of treatment, reducing the probability of surgical treatment and lowering the medical cost.
Description
Technical Field
The utility model belongs to the technical field of medical appliances, and particularly relates to a bracket-free fixed levonorethindrone intrauterine drug delivery device.
Background
The levonorgestrel ring is a commonly used intrauterine drug delivery system, is placed in the uterine cavity and can be maintained to be effective for many years, and the main application of the levonorgestrel ring is contraception, and has the effects of treating excessive menstrual flow, preventing abnormal uterine bleeding, preventing and relieving pain caused by endometriosis and adenomyosis, reducing the risk of ovarian cancer, reducing the risk of occurrence of endometrial polyps of tamoxifen users and the like, and has good curative effect.
The size of the levonorgestrel ring widely used in clinic at present is fixed and the ring is manufactured according to the normal uterus. However, patients with abnormal uterine bleeding are often accompanied by relaxation of the cervical orifice and enlargement of the uterine cavity; many patients with adenomyosis and endometriosis will have enlarged uterus, and when these patients use the existing norethindrone ring, ring detachment, ring dislocation, ring displacement and the like often occur, which results in failure of treatment and may also increase the chance of vaginal bleeding. In order to avoid the problems, the solutions adopted in clinic at present are as follows: the left norethindrone ring is placed upside down, but can irritate the uterus and cause discomfort to the patient; hysteromyoma is sutured and fixed under the hysteroscope, but the operation difficulty is high, the ring taking is complicated, and the clinical application is limited; the ring and the levonorethindrone ring are placed at the same time in a crossed manner, so that the practical application effect is not ideal, and the discomfort of a patient can be increased.
Disclosure of Invention
In order to solve the problems that the existing levonorgestrel ring is easy to fall off, deviate and shift in the use process, and improve the treatment success rate, the inventor prepares a bracket-free fixed intrauterine device for levonorgestrel through continuous fumbling and improvement and research and development after repeated clinical verification in long-term clinical practice, and the device has the characteristics of simple structure, safety, economy, definite curative effect and the like, and is very suitable for the current clinical requirements.
The inventor carries out structural improvement on the existing levonorethindrone ring device used in clinic, firstly proposes a design idea of fixing a medicine container in a uterine cavity by utilizing a linear structure, removes a bracket structure (such as a double-wing bracket or a T-shaped bracket) of the existing treatment ring for fixing, and changes a head wire structure containing an intrauterine fixing knot into a head wire structure, namely, the top end of a medicine storage tank is fixedly connected with a head wire made of polypropylene wire, the front end of the head wire is provided with the intrauterine fixing knot, and the intrauterine fixing knot is buried and fixed in the middle position of an intrauterine muscular layer (preferably a muscular layer of the uterine fundus) by utilizing the physiological thickness of the uterine muscular layer through a Gong Nahuan placer, so that good fixing is realized. The utility model can firmly fix the medicine storage tank in the uterine cavity without fixing the bracket, and can ensure that the medicine storage tank is not shifted and is not fallen no matter the size of the uterine cavity and whether the cervical canal of a patient is loose or not, thereby ensuring the persistence and the effectiveness of treatment; finally, the probability of operation treatment is reduced, and the medical cost is reduced.
Specifically, the utility model provides a stent-free fixed intrauterine device for levonorethindrone, which comprises a drug storage tank 1, a head wire 2 and a tail wire 3; wherein:
the medicine storage tank 1 is long cylindrical with two closed ends, the front end of the medicine storage tank is fixedly connected with the head wire 2 through a connecting ring 5, and the rear end of the medicine storage tank is fixedly connected with the tail wire 3 through the connecting ring 5;
the rear end of the head wire 2 is fixedly connected with the medicine storage tank 1 through a connecting ring 5, and the front end is an intrauterine fixed knot 4.
Further, the medicine storage tank 1 of the stent-free fixed levonorgestrel intrauterine administration device contains a levonorgestrel medicine.
Further, in the stent-free fixed levonorgestrel intrauterine drug delivery device, the drug storage tank 1 is made of polyethylene, and at least one drug release hole is arranged on the surface of the drug storage tank.
Preferably, the headwire 2 and the tail wire 3 in the stent-free fixed levonorgestrel intrauterine drug delivery device are made of polypropylene wires.
Further, the intrauterine fixation knot 4 in the stent-free fixed intrauterine device for the norgestrel is used for fixing the intrauterine device for the norgestrel in the uterine cavity.
Further, the intrauterine fixation knot 4 in the stent-free fixed levonorgestrel intrauterine drug delivery device is mounted and fixed on the intrauterine muscular layer by an intrauterine ring placer comprising a cannula and a push rod.
Further, the fiber 3 in the stent-free fixed levonorgestrel intrauterine drug delivery device is used for taking out the levonorgestrel intrauterine drug delivery device from the uterus.
Preferably, in the stent-free fixed levonorgestrel intrauterine drug delivery device, the length of the drug storage tank 1 is 22-28 mm, the length of the head wire 2 is 11.2-11.5 mm, and the length of the tail wire 3 is 28-29.5 mm.
Further preferably, the length of the drug storage tank 1 in the stent-free fixed levonorgestrel intrauterine drug delivery device is 26mm, the length of the head wire 2 is 11.36mm, and the length of the tail wire 3 is 28.85mm.
In summary, the stent-free fixed intrauterine administration device for levonorgestrel has the following advantages:
(1) The device utilizes the physiological thickness of the myometrium and the linear structure to fix the intrauterine fixation knot at the middle position of the myometrium, thereby realizing good fixation.
(2) The fixing mode adopted by the device is independent of the size of the uterine cavity, so that the limitation of placement of intrauterine therapeutic rings is reduced; the fixing mode of the device is irrelevant to cervical looseness, and the falling off and displacement of the ring are stopped; whether the uterine cavity of the patient is large or not and whether the cervical canal is loose or not, the device can ensure that the medicine storage tank is not shifted or falls off, and the tolerance of the patient is better.
(3) The device has wide application, can be used for treating dysmenorrhea caused by endometriosis, excessive menstrual flow, preventing recurrence of endometrial polyps, treating endometrial lesions, and simultaneously can be used for contraception, ensure the continuity and effectiveness of treatment, reduce the probability of surgical treatment and reduce the medical cost.
(4) The device does not need to be fixed by a bracket, has simple structure, safety, economy and definite curative effect, and is very suitable for the current clinical requirements.
Drawings
For a clearer description of the technical solutions of the embodiments of the present utility model, the drawings that need to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are only specific embodiments described in the present utility model, and other drawings can be obtained according to the following drawings without inventive effort for a person skilled in the art.
Fig. 1 is a schematic view (top view) of the structure of the device of the present utility model.
Fig. 2 is a schematic structural view (side view) of the device of the present utility model.
Drawing and annotating: 1-a medicine storage tank, 2-a head wire, 3-a tail wire, 4-an intrauterine fixed knot and 5-a connecting ring.
Detailed Description
The following description of the embodiments of the present utility model will be made more apparent and fully by reference to the specific embodiments, but the embodiments described are merely some, rather than all, of the embodiments of the present utility model. Other advantages of the present utility model will be readily apparent to those skilled in the art from the disclosure herein. The utility model may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present utility model.
Before the embodiments of the utility model are explained in further detail, it is to be understood that the utility model is not limited in its scope to the particular embodiments described below; the terminology used in the examples of the utility model is for the purpose of describing particular embodiments only and is not intended to be limiting of the scope of the utility model.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this utility model belongs. In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present utility model may be used to practice the present utility model according to the knowledge of one skilled in the art and the description of the present utility model.
In the present utility model, unless otherwise specified, all devices and materials are commercially available or commonly used in the industry.
Example A stent-free fixed Inonone left delivery device (see figures 1-2)
The device comprises a medicine storage tank 1, a head wire 2 and a tail wire 3; wherein:
the medicine storage tank 1 is a long cylinder with two airtight ends, the length is 26mm, the front end of the medicine storage tank is fixedly connected with the head wire 2 through the connecting ring 5, and the rear end of the medicine storage tank is fixedly connected with the tail wire 3 through the connecting ring 5.
The medicine storage tank 1 is made of polyethylene, contains the levonorethindrone medicine, and is provided with a medicine release hole respectively at the front, middle and rear parts of the surface of the medicine storage tank 1.
The head wire 2 and the tail wire 3 are both made of polypropylene wires, the length of the head wire 2 is 11.36mm, the rear end of the head wire 2 is fixedly connected with the drug storage tank 1 through a connecting ring 5, the front end of the head wire is an intrauterine fixed knot 4, and the intrauterine fixed knot 4 is buried and fixed at the middle position of the uterine fundus by an intrauterine ring placer comprising a sleeve and a push rod.
The length of the fiber 3 was 28.85mm for taking out the levonorgestrel intrauterine drug delivery device from the uterus.
While the preferred embodiments and examples of the present utility model have been described in detail, the present utility model is not limited to the above-described embodiments and examples, and various changes may be made within the knowledge of those skilled in the art without departing from the spirit of the present utility model.
Claims (8)
1. The intrauterine device for administering the norethindrone without the support fixation is characterized by comprising a drug storage tank (1), a head wire (2) and a tail wire (3); wherein:
the drug storage tank (1) is long cylindrical with two airtight ends, the front end of the drug storage tank is fixedly connected with the head wire (2) through a connecting ring (5), and the rear end of the drug storage tank is fixedly connected with the tail wire (3) through the connecting ring (5);
the rear end of the head wire (2) is fixedly connected with the medicine storage tank (1) through a connecting ring (5), and the front end is an intrauterine fixed knot (4);
the length of the medicine storage tank (1) is 22-28 mm, the length of the head wire (2) is 11.2-11.5 mm, and the length of the tail wire (3) is 28-29.5 mm.
2. The stent-less fixed intrauterine device of levonorgestrel according to claim 1, wherein the drug reservoir (1) contains a levonorgestrel drug.
3. The stent-free fixed levonorgestrel intrauterine drug delivery device according to claim 1, wherein the drug storage tank (1) is made of polyethylene, the surface of which is provided with at least one drug release hole.
4. The stent-free fixed levonorgestrel intrauterine device according to claim 1, wherein the head wire (2) and the tail wire (3) are made of polypropylene wire.
5. The stent-less fixed intrauterine device of left norethindrone according to claim 1, wherein said intrauterine fixation knot (4) is used for fixing said intrauterine device of left norethindrone in the uterine cavity.
6. The stent-less fixed left norethindrone intrauterine drug delivery device of claim 1, wherein said intrauterine fixation knot (4) is secured to the intrauterine muscular layer by an intrauterine ring placer comprising a cannula and a push rod.
7. The stent-less fixed intrauterine device of levonorgestrel according to claim 1, wherein the fiber (3) is used for withdrawing the intrauterine device of levonorgestrel from the uterus.
8. The stent-free fixed left norethindrone intrauterine drug delivery device according to claim 1, wherein the length of the drug storage tank (1) is 26mm, the length of the head wire (2) is 11.36mm, and the length of the tail wire (3) is 28.85mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202321660905.2U CN220554555U (en) | 2023-06-28 | 2023-06-28 | Non-bracket fixed levonorethindrone intrauterine drug delivery device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202321660905.2U CN220554555U (en) | 2023-06-28 | 2023-06-28 | Non-bracket fixed levonorethindrone intrauterine drug delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN220554555U true CN220554555U (en) | 2024-03-05 |
Family
ID=90052555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202321660905.2U Active CN220554555U (en) | 2023-06-28 | 2023-06-28 | Non-bracket fixed levonorethindrone intrauterine drug delivery device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN220554555U (en) |
-
2023
- 2023-06-28 CN CN202321660905.2U patent/CN220554555U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200222230A1 (en) | Intra uterine device | |
| US3913573A (en) | Intrauterine contraceptive devices with plural parallel leg segments | |
| Lu et al. | A long term follow-up study of 1,055 cases of postpartum tubal ligation | |
| Mishell Jr et al. | A study of the copper T intrauterine contraceptive device (TCu 200) in nulliparous women | |
| Kennedy | 2 Post-partum contraception | |
| CN220554555U (en) | Non-bracket fixed levonorethindrone intrauterine drug delivery device | |
| Newton et al. | Intrauterine contraception using the copper-seven device | |
| Wildemeersch et al. | Intrauterine contraception in the year 2001: can intrauterine device use be revived with new improved contraceptive technology? | |
| Hermanto et al. | Family planning program and its impacts to women’s health according to the perspective of Islamic Law | |
| CN207821889U (en) | Asherman's syndrom curer | |
| Yu et al. | Spontaneous expulsion of a uterine submucosal leiomyoma after administration of a gonadotropin-releasing hormone agonist | |
| Adinma | Cervical polyp presenting as inevitable abortion | |
| LEHFELDT et al. | Unusual uterine perforation with a new intrauterine device | |
| Guillebaud | Contraception for the older woman | |
| CN217014344U (en) | Foursquare vertical uterine cavity support | |
| Bobrow et al. | Amenorrhoea despite displaced levonorgestrel intra-uterine system | |
| CN209122602U (en) | A kind of common oviduct IUD | |
| Townsend | Postpartum options: matching the method to individual needs | |
| Mazza | Take a fresh look at IUDs. Things have changed | |
| Guidetti et al. | Non-surgical tubal embryo transfer | |
| Nurfajriah | POSTPARTUM CONTRACEPTION | |
| Bakri | Use of Intra Uterine Devices in Family Planning | |
| RU2138229C1 (en) | Pessary | |
| Mehtaji et al. | Chemical sterilization with quinacrine | |
| Lee et al. | Corpus luteal cyst Rupture with Tubal Abortion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |